Chronic Obstructive Pulmonary Disease: Market Research Report
This report analyzes the worldwide markets for Chronic Obstructive Pulmonary Disease in US$ Million.
The report provides separate comprehensive analytics for US and Rest of World.
Annual forecasts are provided for each region for the period 2006 through 2015.
The report profiles 53 companies including many key and niche players worldwide such as AstraZeneca Plc, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Novartis AG, Nycomed S.C.A.
SICAR, Schering-Plough Corporation, Sepracor, Inc., and Vectura Group plc.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
The report provides separate comprehensive analytics for US and Rest of World.
Annual forecasts are provided for each region for the period 2006 through 2015.
The report profiles 53 companies including many key and niche players worldwide such as AstraZeneca Plc, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Novartis AG, Nycomed S.C.A.
SICAR, Schering-Plough Corporation, Sepracor, Inc., and Vectura Group plc.
Market data and analytics are derived from primary and secondary research.
Company profiles are mostly extracted from URL research and reported select online sources.
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1.INDUSTRY OVERVIEW
Respiratory Diseases – Common and Serious
COPD – A Debilitating Disease
COPD Fact File: Prevalence
COPD Fact File: Mortality
COPD Fact File: Smoking as the Leading Cause
COPD - Economic Burden
2.MARKET DYNAMICS
Current & Future Analysis
Market Overview
Market Outlook
Maintenance Therapies to Continue Lead
Treatment of Inflammation – An Unmet Need
Competitive Landscape
3.COPD PIPELINE
The COPD Drug Discovery
Bronchodilators Pipeline
List of Potential Bronchodilator (LABA Inhaled) Candidates in Drug Development Pipeline
List of Potential Bronchodilator (LAMA Inhaled) Candidates in Drug Development Pipeline
Anti-inflammatories Pipeline
List of Potential Anti-inflammatory (Inhaled Corticosteroid) Candidates in Drug Development Pipeline
List of Potential Anti-inflammation Agents (Anti- Leukotriene-oral) Candidates in Drug Development Pipeline
List of Potential Anti-inflammation Agents (Phophodiesterase-4 Inhibitors-oral) Candidates in Drug Development Pipeline
Combination Products Pipeline
List of Potential Combination Products (LABA/ICS Combination-inhaled) in Drug Development Pipeline
List of Potential Combination Products (LABA/LAMA) in Drug Development Pipeline
Pipeline Drugs with Novel Mode of Action
List of Novel Approaches to COPD Treatment in Drug Development Pipeline
4.CHRONIC OBSTRUCTIVE PULMONARY DISEASE – THE CONDITION AND TREATMENT
Chronic Obstructive Pulmonary Disease – Synopsis
The Normal Lung Functioning
The Lung Functioning in COPD
Risk Factors
Signs and Symptoms
Diagnosis
The Misconception
Management Guidelines
GOLD Recommended Management of COPD: Stage 0
GOLD Recommended Management of COPD: Stage II
GOLD Recommended Management of COPD: Stage III
GOLD Recommended Management of COPD: Stage IV
Treatment Options
Therapeutic Options
Bronchodilators
Beta2-agonists
Short-acting Beta2-agonists
List of Prescription Short-acting Beta2-agonists
Long-acting Beta2-agonists
A Comparison of Leading Two LABAs : Salmeterol and Formoterol
List of Prescription Long-acting Beta2-agonists
Anticholinergics
Short-acting Anticholinergics
List of Short-acting Prescription Anticholinergics
Long-acting Anticholinergics
Methylxanthines
List of Methylxanthines and Their Route of Administration
Anti-inflammatories
Inhaled Steroids
List of Inhaled Steroids and their Route of Administration
Oral Steroids
List of Tablet Steroids and their Route of Administration
Combination Therapies
List of Prescription Combination Products
5.RECENT INDUSTRY ACTIVITY
AEterna Zentaris Signs Agreement to Acquire All AEZS-130 Assets from Ardana
Nycomed and Forest Sign Exclusive US Accord for Daxas
Schering-Plough Revises Collaboration with Novartis
AstraZeneca Extends Research Collaboration with Dynavax
GlaxoSmithKline and Mitsubishi Tanabe Sign Co-marketing Deal for Adoair
SeQual Technologies and AOTI Form Partnership
Revotar Biopharma Secures Research Grant
Argenta Discovery Announces Milestone Achievement
Vectura Receives Milestone Payment
Vectura Inaugurates New Laboratory Facility
MicroDose Technologies Announces Name Change to MicroDose Therapeutx
Boehringer Ingelheim to Take Over Actimis Pharmaceuticals
Novartis to Acquire Pulmonary Unit of Nektar
Tongjitang Chinese Medicine Plans Pulante Pharma Acquisition
Sepracor, Arrow Announce Global Agreement for Combination Inhalation Solution
Nycomed Canada and Chiesi Farmaceutici form Licensing Agreement
Sepracor, Arrow Sign Technology License and Development Agreement
Teva Specialty Pharmaceuticals Announces Respiratory Deal with UCB
3M DRUG DELIVERY AND CAMBRIDGE CONSULTANTS SIGN EXCLUSIVE AGREEMENT
Sanofi-aventis Announces Collaboration with Johns Hopkins University
Lupin Enters Long-Term Accord with Forest Laboratories
Ingen Signs Agreements with Batterjee Medical and Progressive International
AstraZeneca, Silence Therapeutics Enter into Collaboration
Vectura Announces Sandoz as Partner for VR315 and VR632
Air Products Divests A&J Care and COPD Services
Parion Sciences Receives Milestone Payment for Pulmonary Disease Drug
Almirall Receives Payment from Forest Laboratories for Aclidinium Bromide
AstraZeneca Announces EPO Ruling for Symbicort Patent
Inverness Medical Announces Alere Medical Acquisition
Respironics Takes Over J.H. Emerson
Alkermes Enters into Joint Collaboration with Indevus Pharmaceuticals
Aradigm Enters into Collaboration Agreement with CyDex
Critical Therapeutics and Dey Sign Co-Promotion Agreement
6.PRODUCT APPROVALS / INTRODUCTIONS
AstraZeneca Wins US Approval for Symbicort
Novartis Secures EC Approval for New Oral COPD Drug, Onbrez Breezhaler
Nycomed Submits MMA for New Oral Drug, Daxas, to the EMEA
Nycomed Files for Daxas® Approval with the FDA
Novartis Receives FDA’s CRL for Investigational COPD Bronchodilator, QAB149
3M DRUG DELIVERY LAUNCHES TWO NEW DRY POWDER INHALERS
GlaxoSmithKline Announces FDA Approval of Advair Diskus 250/50
Dey’s Perforomist Inhalation Solution Wins FDA Approval for COPD
Boehringer, Pfizer Win EU Approval for Spiriva Respimat
7.FOCUS ON SELECT PLAYERS
AstraZeneca Plc (UK)
Boehringer Ingelheim GmbH (Germany)
GlaxoSmithKline PLC (UK)
Novartis AG (Switzerland)
Nycomed S.C.A. SICAR (Switzerland)
Schering-Plough Corporation (US)
Sepracor, Inc. (US)
Vectura Group plc (UK)
8.GLOBAL MARKET PERSPECTIVE
III. MARKET
1.THE UNITED STATES
A. MARKET ANALYSIS
Current & Future Analysis
COPD – Prevalence
Chronic Bronchitis Data
Emphysema Data
Market Overview
Patient Non-compliance Hinders Market Growth
Lack of Awareness – A Major Bottleneck for Market Growth
HFA-propelled Inhalers End the CFC-propelled Inhalers Era
Strategic Corporate Developments
Product Approvals / Launches
Select Players
B. MARKET ANALYTICS
2.REST OF WORLD
A. MARKET ANALYSIS
Current & Future Analysis
China
Market Overview
Strategic Corporate Developments
Product Approvals
Select Players
B. MARKET ANALYTICS
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 53 (including Divisions/Subsidiaries - 56)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Rest of Europe
Asia-Pacific (Excluding Japan)
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1.INDUSTRY OVERVIEW
Respiratory Diseases – Common and Serious
COPD – A Debilitating Disease
COPD Fact File: Prevalence
COPD Fact File: Mortality
COPD Fact File: Smoking as the Leading Cause
COPD - Economic Burden
Table 1. COPD Related Costs (Including Direct and Indirect Costs) Per Patient Aged Over 40 Years (includes corresponding Graph/Chart)
2.MARKET DYNAMICS
Current & Future Analysis
Market Overview
Market Outlook
Maintenance Therapies to Continue Lead
Treatment of Inflammation – An Unmet Need
Competitive Landscape
Table 2. World COPD Market by Major Drugs (2006): Value Sales for Advair, Spiriva, Combivent, Symbicort, and Atrovent (includes corresponding Graph/Chart)
Table 3. World Leading Inhaled COPD/Asthma Drugs (2007): Value Sales for Advair, Symbicort, Pulmicort, Flovent, Asmanex, Serevent, Foradil, Spiriva, Atrovent, Combivent (includes corresponding Graph/Chart)
3.COPD PIPELINE
The COPD Drug Discovery
Bronchodilators Pipeline
List of Potential Bronchodilator (LABA Inhaled) Candidates in Drug Development Pipeline
List of Potential Bronchodilator (LAMA Inhaled) Candidates in Drug Development Pipeline
Anti-inflammatories Pipeline
List of Potential Anti-inflammatory (Inhaled Corticosteroid) Candidates in Drug Development Pipeline
List of Potential Anti-inflammation Agents (Anti- Leukotriene-oral) Candidates in Drug Development Pipeline
List of Potential Anti-inflammation Agents (Phophodiesterase-4 Inhibitors-oral) Candidates in Drug Development Pipeline
Combination Products Pipeline
List of Potential Combination Products (LABA/ICS Combination-inhaled) in Drug Development Pipeline
List of Potential Combination Products (LABA/LAMA) in Drug Development Pipeline
Pipeline Drugs with Novel Mode of Action
List of Novel Approaches to COPD Treatment in Drug Development Pipeline
4.CHRONIC OBSTRUCTIVE PULMONARY DISEASE – THE CONDITION AND TREATMENT
Chronic Obstructive Pulmonary Disease – Synopsis
The Normal Lung Functioning
The Lung Functioning in COPD
Risk Factors
Signs and Symptoms
Diagnosis
The Misconception
Management Guidelines
GOLD Recommended Management of COPD: Stage 0
GOLD Recommended Management of COPD: Stage II
GOLD Recommended Management of COPD: Stage III
GOLD Recommended Management of COPD: Stage IV
Treatment Options
Therapeutic Options
Bronchodilators
Beta2-agonists
Short-acting Beta2-agonists
List of Prescription Short-acting Beta2-agonists
Long-acting Beta2-agonists
A Comparison of Leading Two LABAs : Salmeterol and Formoterol
List of Prescription Long-acting Beta2-agonists
Anticholinergics
Short-acting Anticholinergics
List of Short-acting Prescription Anticholinergics
Long-acting Anticholinergics
Methylxanthines
List of Methylxanthines and Their Route of Administration
Anti-inflammatories
Inhaled Steroids
List of Inhaled Steroids and their Route of Administration
Oral Steroids
List of Tablet Steroids and their Route of Administration
Combination Therapies
List of Prescription Combination Products
5.RECENT INDUSTRY ACTIVITY
AEterna Zentaris Signs Agreement to Acquire All AEZS-130 Assets from Ardana
Nycomed and Forest Sign Exclusive US Accord for Daxas
Schering-Plough Revises Collaboration with Novartis
AstraZeneca Extends Research Collaboration with Dynavax
GlaxoSmithKline and Mitsubishi Tanabe Sign Co-marketing Deal for Adoair
SeQual Technologies and AOTI Form Partnership
Revotar Biopharma Secures Research Grant
Argenta Discovery Announces Milestone Achievement
Vectura Receives Milestone Payment
Vectura Inaugurates New Laboratory Facility
MicroDose Technologies Announces Name Change to MicroDose Therapeutx
Boehringer Ingelheim to Take Over Actimis Pharmaceuticals
Novartis to Acquire Pulmonary Unit of Nektar
Tongjitang Chinese Medicine Plans Pulante Pharma Acquisition
Sepracor, Arrow Announce Global Agreement for Combination Inhalation Solution
Nycomed Canada and Chiesi Farmaceutici form Licensing Agreement
Sepracor, Arrow Sign Technology License and Development Agreement
Teva Specialty Pharmaceuticals Announces Respiratory Deal with UCB
3M DRUG DELIVERY AND CAMBRIDGE CONSULTANTS SIGN EXCLUSIVE AGREEMENT
Sanofi-aventis Announces Collaboration with Johns Hopkins University
Lupin Enters Long-Term Accord with Forest Laboratories
Ingen Signs Agreements with Batterjee Medical and Progressive International
AstraZeneca, Silence Therapeutics Enter into Collaboration
Vectura Announces Sandoz as Partner for VR315 and VR632
Air Products Divests A&J Care and COPD Services
Parion Sciences Receives Milestone Payment for Pulmonary Disease Drug
Almirall Receives Payment from Forest Laboratories for Aclidinium Bromide
AstraZeneca Announces EPO Ruling for Symbicort Patent
Inverness Medical Announces Alere Medical Acquisition
Respironics Takes Over J.H. Emerson
Alkermes Enters into Joint Collaboration with Indevus Pharmaceuticals
Aradigm Enters into Collaboration Agreement with CyDex
Critical Therapeutics and Dey Sign Co-Promotion Agreement
6.PRODUCT APPROVALS / INTRODUCTIONS
AstraZeneca Wins US Approval for Symbicort
Novartis Secures EC Approval for New Oral COPD Drug, Onbrez Breezhaler
Nycomed Submits MMA for New Oral Drug, Daxas, to the EMEA
Nycomed Files for Daxas® Approval with the FDA
Novartis Receives FDA’s CRL for Investigational COPD Bronchodilator, QAB149
3M DRUG DELIVERY LAUNCHES TWO NEW DRY POWDER INHALERS
GlaxoSmithKline Announces FDA Approval of Advair Diskus 250/50
Dey’s Perforomist Inhalation Solution Wins FDA Approval for COPD
Boehringer, Pfizer Win EU Approval for Spiriva Respimat
7.FOCUS ON SELECT PLAYERS
AstraZeneca Plc (UK)
Boehringer Ingelheim GmbH (Germany)
GlaxoSmithKline PLC (UK)
Novartis AG (Switzerland)
Nycomed S.C.A. SICAR (Switzerland)
Schering-Plough Corporation (US)
Sepracor, Inc. (US)
Vectura Group plc (UK)
8.GLOBAL MARKET PERSPECTIVE
Table 4. World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease by Geographic Region – US and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
Table 5. World 10-Year Perspective for Chronic Obstructive Pulmonary Disease by Geographic Region - Percentage Breakdown of Dollar Revenues for the US and Rest of World Markets for 2006, 2009 & 2015
III. MARKET
1.THE UNITED STATES
A. MARKET ANALYSIS
Current & Future Analysis
COPD – Prevalence
Table 6. COPD Prevalence Data in American Adults Aged 18 Years and Over in the US (includes corresponding Graph/Chart)
Chronic Bronchitis Data
Table 7. Chronic Bronchitis - Breakdown of Chronic Bronchitis Patients by Gender: 2007
Table 8. Chronic Bronchitis - Breakdown of Chronic Bronchitis Patients by Age Group: 2007 (includes corresponding Graph/Chart)
Table 9. Chronic Bronchitis - Breakdown of Chronic Bronchitis Patients by Ethnicity: 2007 (includes corresponding Graph/Chart)
Emphysema Data
Table 10. Emphysema - Breakdown of Chronic Bronchitis Patients by Gender: 2007
Table 11. Emphysema - Breakdown of Chronic Bronchitis Patients by Age Group: 2007 (includes corresponding Graph/Chart)
Table 12. Emphysema - Breakdown of Chronic Bronchitis Patients by Ethnicity: 2007 (includes corresponding Graph/Chart)
Market Overview
Table 13. US COPD Market by Major Drugs (2006): Value Sales for Advair, Spiriva, Combivent, Flovent, Atrovent, and Serevent (includes corresponding Graph/Chart)
Table 14. US COPD Market by Major Drugs (2006): Total Prescriptions for Advair, Spiriva, Combivent, Flovent, Atrovent, and Serevent (includes corresponding Graph/Chart)
Table 15. US COPD/Asthma Market by Drug Class (2007 and 2008): Value Sales for Inhaled Steroids/ Combinations, Inhaled Beta Agonists, Leukotrines, and Inhaled Anticholinergics/NSAIDs (includes corresponding Graph/Chart)
Table 16. US COPD/Asthma Market by Drug Class (2007 and 2008): Total Prescriptions for Inhaled Steroids/ Combinations, Inhaled Beta Agonists, Leukotrines, and Inhaled Anticholinergics/NSAIDs (includes corresponding Graph/Chart)
Table 17. US COPD/Asthma Market by Leading Drugs (2007 and 2008): Value Sales for Advair/Diskus, Singulair, Spiriva, Symbicort, Pulmicort, and Flovent (includes corresponding Graph/Chart)
Table 18. US COPD/Asthma Market by Leading Drugs (2007 and 2008): Total Number of Prescriptions for Advair/Diskus, Singulair, Spiriva, Symbicort, Pulmicort, and Flovent (includes corresponding Graph/Chart)
Patient Non-compliance Hinders Market Growth
Lack of Awareness – A Major Bottleneck for Market Growth
HFA-propelled Inhalers End the CFC-propelled Inhalers Era
Strategic Corporate Developments
Product Approvals / Launches
Select Players
B. MARKET ANALYTICS
Table 19. US Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease – Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
2.REST OF WORLD
A. MARKET ANALYSIS
Current & Future Analysis
China
Market Overview
Strategic Corporate Developments
Product Approvals
Select Players
B. MARKET ANALYTICS
Table 20. Rest of World Recent Past, Current & Future Analysis for Chronic Obstructive Pulmonary Disease – Annual Revenue Figures in US$ Million for Years 2006 through 2015 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 53 (including Divisions/Subsidiaries - 56)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Rest of Europe
Asia-Pacific (Excluding Japan)
